FDA grants Fast Track designation to glutaminase inhibitor combination for metastatic kidney cancer

The glutaminase inhibitor, CB-839 has been granted Fast Track designation by the US Food and Drug Administration (FDA) in combination with cabozantinib (Cabometyx) for the treatment of people with metastatic renal cell carcinoma (mRCC) who have previously received one or two drug treatments.

The FDA’s Fast Track programme speeds up the development, review and approval of drugs for serious and life-threatening conditions by allowing more interaction between the FDA and the manufacturer.

Read more in Targeted Oncology here

Share this Post!


Related post

  TOP